Ensysce Biosciences
US-based Ensysce Biosciences develops safer prescription drugs to reduce abuse and prevent overdoses.
- 7
- Public company
- La Jolla, CA, USUnited States
US-based Ensysce Biosciences develops safer prescription drugs to reduce abuse and prevent overdoses.
ensysce.comCrawled Sep 24, 2026
En + Cy is pioneering small molecule therapies that treat chronic pain by targeting its root cause via the central nervous system.
Ensysce Biosciences’ President James Morrison engages Middle East family offices to advance the company’s **CY200 therapy**, targeting **Complex Regional Pain Syndrome (CRPS)**. The clinical-stage biotech focuses on neuroplastogenic treatments beyond mood disorders. The outreach aims to strengthen global investor and strategic partnerships.
Oct 2026Yahoo FinanceNews article
Ensysce Biosciences, a clinical-stage biotech firm, announces its attendance at upcoming investor conferences and industry events. The company focuses on neuroplastogenic therapies for conditions beyond mood disorders, including CRPS (Complex Regional Pain Syndrome). Participation aims to engage with stakeholders and showcase its pipeline.
Sep 2026Yahoo FinanceNews article
Ensysce Biosciences completes the acquisition of Cy Biopharma, gaining access to its drug candidate **CY200** for treating **Complex Regional Pain Syndrome**. The deal secures up to **$77 million** in new funding for the company. Ensysce will host a corporate update call on **August 18, 2026**, to discuss further details.
Aug 2026Ensysce Biosciences, Inc.News article
Ensysce Biosciences acquires Cy Biopharma, gaining access to a clinical-stage neuroplastogenic therapy designated as an **Orphan Drug** by the **U.S. FDA** for treating **Complex Regional Pain Syndrome**. The deal includes up to **$77 million** in private financing to support development. The therapy targets a rare, debilitating pain condition with limited treatment options.
Aug 2026Ensysce Biosciences, Inc.News article